Skip to content

Study · Randomized controlled trial · n = 19 · 2019

2 results

Intranasal oxytocin alters amygdala-temporal resting-state functional connectivity in body dysmorphic disorder: A double-blind placebo-controlled randomized trial.

Grace SA, Labuschagne I, Castle DJ, Rossell SL

Psychoneuroendocrinology22 May 2019Cited by 18 (Europe PMC)

PMID31146138 (opens in a new tab)DOI10.1016/j.psyneuen.2019.05.022 (opens in a new tab)PepBankPUB-31146138
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In people with body dysmorphic disorder, the greater left amygdala-temporal and superior frontal resting-state connectivity seen with placebo, compared with healthy controls, was reversed after intranasal oxytocin.

    In plain wordsIn people with body dysmorphic disorder, oxytocin reversed an unusual pattern of brain connectivity seen with placebo.

    Peptide
    Oxytocin
    Outcome
    MixedAmygdala-temporal resting-state connectivity in body dysmorphic disorder
    Study

    n = 19

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Compared to healthy controls, BDD patients showed greater baseline (placebo) rsFC between the left amygdala and two clusters within the left temporal lobe and one cluster within the superior frontal gyrus which was reversed following OXT administration.
    1 context sentence
    Summary · context
    In a randomized, double-blind, cross-over design, 19 BDD participants and 17 demographically matched healthy control participants received intranasal OXT (24 IU) or placebo prior to resting-state functional magnetic resonance imaging.
  2. 02HumanRandomized controlled trialMechanism

    In healthy controls, intranasal oxytocin increased resting-state connectivity between the left amygdala and anterior prefrontal cortex versus placebo.

    In plain wordsIn healthy people, oxytocin increased connectivity between two brain areas compared with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseLeft amygdala to anterior prefrontal cortex connectivity in healthy controls
    Study

    n = 17

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    The control group also showed significantly greater rsFC between the left amygdala and anterior prefrontal cortex in the OXT session compared to placebo.
    1 context sentence
    Summary · context
    In a randomized, double-blind, cross-over design, 19 BDD participants and 17 demographically matched healthy control participants received intranasal OXT (24 IU) or placebo prior to resting-state functional magnetic resonance imaging.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.